About Double C2-like domain-containing protein alpha
Double C2-like domain-containing protein alpha (DOC2A) is a protein
from Homo sapiens identified by UniProt accession
Q14183, 400 residues long.
MolForge cross-references it against 0 known binders and
85 disease associations.
Target properties
| Protein name | Double C2-like domain-containing protein alpha |
| UniProt accession | Q14183 |
| Gene | DOC2A |
| Organism | Homo sapiens |
| Length | 400 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (85)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.41
- body height · score 0.30
- lean body mass · score 0.27
- sex hormone-binding globulin measurement · score 0.25
- appendicular lean mass · score 0.25
- body mass index · score 0.23
- grip strength measurement · score 0.22
- Diuretic use measurement · score 0.17
- type 2 diabetes mellitus · score 0.16
- diet measurement · score 0.16
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14183-F1 | alphafold | PREDICTED | 77.99 | — |
Amino-acid sequence (400 residues)
MRGRRGDRMT INIQEHMAIN VCPGPIRPIR QISDYFPRGP GPEGGGGGGG EAPAHLVPLA LAPPAALLGA TTPEDGAEVD SYDSDDATAL GTLEFDLLYD RASCTLHCSI LRAKGLKPMD FNGLADPYVK LHLLPGACKA NKLKTKTQRN TLNPVWNEDL TYSGITDDDI THKVLRIAVC DEDKLSHNEF IGEIRVPLRR LKPSQKKHFN ICLERQVPLA SPSSMSAALR GISCYLKELE QAEQGQGLLE ERGRILLSLS YSSRRRGLLV GILRCAHLAA MDVNGYSDPY VKTYLRPDVD KKSKHKTCVK KKTLNPEFNE EFFYEIELST LATKTLEVTV WDYDIGKSND FIGGVSLGPG ARGEARKHWS DCLQQPDAAL ERWHTLTSEL PPAAGALSSA
Explore Double C2-like domain-containing protein alpha with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets